GordonMD Global Investments LP holds a concentrated book of 16 stocks worth $143.6M as of Q1 2026 (disclosed May 15, 2026, a ~45-day 13F lag). This quarter they opened Scholar Rock Holding Corp and trimmed Kyverna Therapeutics Inc. Their largest long position is Kyverna Therapeutics Inc at 26% of the equity book.
Top-heavy: concentrated book
Share of the disclosed book in its largest positions. A higher top-5 share means a more concentrated, higher-conviction portfolio.
100% mapped to company sectors
Direct operating-company sectors from our SIC-based security master. ETF/fund and unclassified holdings stay visible separately; this is not ETF look-through exposure.
Estimated $ traded · quarter-end prices (an exit at the prior quarter-end), no cost basis
Other tracked managers holding the same core names as GordonMD Global Investments LP
| Manager / fund | Shared names | Their $ in those |
|---|---|---|
| Pfizer Inc | 2 / 16 | $66.4M |
| Redmile Group, LLC | 2 / 16 | $454.0M |
| Baker Bros. Advisors LP | 6 / 16 | $4.2B |
| Bellevue Group AG | 8 / 16 | $812.3M |
| Eagle Health Investments LP | 3 / 16 | $101.0M |
| Ishara Investments LP | 5 / 16 | $20.7M |
| Superstring Capital Management LP | 3 / 16 | $22.2M |
| Siren, L.L.C. | 4 / 16 | $673.7M |
Ranked by the share of each fund's own book sitting in the names it shares with GordonMD Global Investments LP: only funds sharing at least a tenth of the book qualify. Index giants, bank custody books and market makers are excluded. They hold everything, so their overlap says nothing.
Bars show each stock's share of the portfolio. Click a row for its position history.
| # | Security | Value | Shares | % Port | Last move | History |
|---|---|---|---|---|---|---|
| 1 | Kyverna Therapeutics Inc COM | $36.6M | 4.24M | 25.5% | ▼−3.3% Reduced · −147K sh | |
| 2 | Taysha Gene Therapies Inc COM SHS | $22.2M | 737.5K | 15.5% | ▼−45% Reduced · −593K sh | |
| 3 | Vir Biotechnology Inc COM | $13.6M | 1.52M | 9.5% | ▲+63% Added · +588K sh | |
| 4 | Bausch Plus Lomb Corp COMMON SHARES | $9.1M | 573.5K | 6.4% | ▼−6.5% Reduced · −40K sh | |
| 5 | Amgen Inc COM | $7.1M | 20.2K | 5.0% | ▼−13% Reduced · −3K sh | |
| 6 | Scholar Rock Hldg Corp COM | $6.5M | 132.5K | 4.5% | ▲New New position | |
| 7 | Ultragenyx Pharmaceutical In COM | $6.1M | 289.1K | 4.2% | ▼−12% Reduced · −40K sh | |
| 8 | Pyxis Oncology Inc COMMON STOCK | $6.0M | 4.12M | 4.2% | —Held | |
| 9 | Teva Pharmaceutical Inds Ltd SPONSORED ADS | $5.6M | 1.26M | 3.9% | ▲+63% Added · +488K sh | |
| 10 | Sionna Therapeutics Inc COM | $5.5M | 136.0K | 3.8% | ▲New New position | |
| 11 | Celldex Therapeutics Inc New COM NEW | $5.4M | 170.3K | 3.8% | —Held | |
| 12 | Insmed Inc COM PAR $.01 | $4.7M | 28.6K | 3.3% | —Held | |
| 13 | Crinetics Pharmaceuticals In COM | $4.6M | 127.0K | 3.2% | ▼−43% Reduced · −97K sh | |
| 14 | Incyte Corp COM | $4.1M | 43.3K | 2.8% | ▼−21% Reduced · −11K sh | |
| 15 | Allogene Therapeutics Inc COM | $3.5M | 1.43M | 2.4% | ▲New New position | |
| 16 | Tarsus Pharmaceuticals Inc COM | $3.0M | 42.7K | 2.1% | ▼−36% Reduced · −24K sh |
This fund page is the Follow view. The Build view lets your agent pull holdings, quarter changes, overlap, and source filings through API or MCP.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/funds/2039349/holdings"
Use Arkolith to show GordonMD Global Investments LP's latest holdings, largest changes, and filing provenance.
As-of date vs the date the SEC received each filing
Reported 13F total per quarter. Raw filing totals can include option notional.
Holdings from SEC EDGAR 13F-HR filings, updated quarterly, filed up to 45 days after quarter-end. Public domain. The book and weighting are long equity only; disclosed put/call options are listed separately and excluded from those totals. Price-derived performance is withheld until the price-source policy and freshness gate are green.